Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Lineage Cell Therapeutics’ OpRegen holds potential to become new treatment option for GA, says GlobalData

Lineage Cell Therapeutics’ OpRegen (RG6501) is gaining attention as a promising one-time allogenic cell therapy for geographic atrophy (GA), following encouraging results from its Phase I/IIa trial. With limited treatment options currently available, OpRegen’s ability to improve and stabilize vision positions it as a potential breakthrough in addressing a critical unmet need in GA management, […]
Read more

Challenges mount for big pharma in China as vaccine sales plummet, says GlobalData

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China’s vaccine market, as regulatory scrutiny, domestic competition, and changing consumer behaviors disrupt a once-thriving sector. Major players like Merck & Co. and GSK are re-evaluating their strategies in light of these developments, says GlobalData, a leading data and analytics company. GlobalData’s Q2 2025 Emerging Market […]
Read more

High costs and limited access threaten progress in HIV treatment despite new drug advances, says GlobalData

Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious challenges that threaten long-term control of the disease. The most pressing issue is the lack of affordable access to newer therapies, which—despite offering better adherence and fewer side effects—remain out of reach for many patients due to high costs […]
Read more

Vutrisiran to change ATTR-CM treatment paradigm in Europe, says GlobalData

Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. It can cause ATTR-cardiomyopathy (ATTR-CM) or ATTR-polyneuropathy (ATTR-PN). As effective treatments for ATTR-CM are still limited, Alnylam Pharmaceuticals’ drug vutrisiran is expected to change ATTR-CM treatment paradigm upon market launch in Europe, […]
Read more

Nontuberculous mycobacteria market to reach $4.6 billion in 7MM in 2033, forecasts GlobalData

The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 8.8% from $2.0 billion in 2023 to $4.6 billion in 2033, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast”, reveals that […]
Read more

Diagnosed prevalent cases of multiple sclerosis to increase by 0.19% AGR in 7MM during 2024-34, forecasts GlobalData

The diagnosed prevalent cases of multiple sclerosis (MS) in the seven major markets (7MM*) are projected to increase from 1.61 million in 2024 to 1.64 million in 2034 at an annual growth rate (AGR) of negative 0.19%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Multiple Sclerosis Epidemiology Analysis and Forecast to […]
Read more

Diagnosed prevalent cases of pulmonary arterial hypertension to decline by 0.08% AGR in 7MM during 2024-34, forecasts GlobalData

The diagnosed prevalent cases of pulmonary arterial hypertension (PAH) in the seven major markets (*7MM) are projected to decrease from 76,645 in 2024 to 76,035 in 2034 at an annual growth rate (AGR) of negative 0.08%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Pulmonary Arterial Hypertension (PAH) – Epidemiology Analysis and […]
Read more

Rising obesity cases in India present significant growth opportunities for both foreign and domestic companies, says GlobalData

Obesity is a growing public health concern in India, impacting individuals of all ages and increasing the risk of chronic diseases such as diabetes, heart disease, and hypertension. Driven by unhealthy diets, sedentary lifestyles, and environmental factors, obesity is rising rapidly, impacting both urban and rural populations. This trend is driving market growth, particularly within […]
Read more

Merck’s Enflonsia to gain competitive advantage in paediatric RSV prophylaxis market with lack of weight-based dosing, says GlobalData

Merck’s Enflonsia (clesrovimab) has received FDA approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. Enflonsia is a long-acting monoclonal antibody (mAb) that can provide protection through a typical 5-month RSV season with a 105mg dose, regardless of […]
Read more

PureTech’s LYT-100 holds potential to expand treatment options for idiopathic pulmonary fibrosis, says GlobalData

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring of lung tissue, leading to impaired lung function and respiratory symptoms. The emerging therapies aim to address unmet needs in IPF management by targeting specific fibrotic pathways. Therapies such as LYT-100 by PureTech, currently in Phase IIb clinical trials, show promise in […]
Read more

EyePoint’s Duravyu holds potential to become new treatment option for wAMD, says GlobalData

EyePoint Pharmaceuticals’ Duravyu (vorolanib) is in the spotlight following its recent advancements in its Phase III trial. The company recently announced the completion of patient enrollment for LUGANO, its pivotal Phase III clinical trial. The current wet age-related macular degeneration (wAMD) treatment landscape is largely dominated by vascular endothelial growth factor (VEGF) inhibitors. Duravyu is […]
Read more
1 … 8 9 10 11 12 … 110